by Christopher Wells, PMC Communications Director
In a report recently published online in Clinical Cancer Research, representatives from the co-convening organizations of the Turning the Tide Against Cancer initiative say alternative payment models (APMs) should incentivize the adoption of innovative medicines and technologies like those associated with personalized medicine.
“Ultimately, APMs can be a powerful means of driving innovation in treatment and care delivery, facilitating research and promoting access for patients with cancer to proven, individualized, life-changing treatments,” the authors write in a piece titled “The Impact of Alternative Payment Models on Oncology Innovation and Patient Care.” The authors warn about unintended consequences of APMs that are put in place with consideration only to the cost of therapies.
The report was co-authored by Amy M. Miller, Ph.D., Executive Vice President, PMC; Gilbert Omenn, M.D., Ph.D., Director, Center for Computational Medicine and Bioinformatics, University of Michigan, Chair of the American Association for Cancer Research (AACR) Health Policy Committee; and Marcia Kean, Chairman, Feinstein Kean Healthcare. The authors used the results of a multidisciplinary round table on APMs to identify five critical considerations for the development of APMs. They include:
- APMs should keep pace with rapidly emerging science by incentivizing the adoption of innovative medicines and technologies that have the potential to improve patient outcomes and make health care more efficient
- APMs should include mechanisms to encourage patient participation as appropriate in clinical trials as well as ongoing post-market clinical research
- Clinical pathways should be transparent and evidence-based, and updated regularly to reflect current scientific evidence and clinical advances within the overall continuum of care
- When providers and patients are making treatment decisions, patients should be given a clear, comprehensive picture of their treatment options, including cost information that is tailored to the specific patient’s insurance coverage and treatment plan
- APMs should require that clinical data be aggregated and integrated into providers’ workflows via electronic health records in order to support learning health care systems
The recommendations were discussed during a panel session at AACR’s 2016 annual meeting on Sunday, April 17, which Omenn moderated.